Symposium Chair: Constance Chu, MD
Co-Chairs: William Maloney, MD; Jeremy Mao, DDS, PhD; Scott Rodeo, MD; and Rocky Tuan, PhD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)/NIH Advisor: Fei Wang, PhD
Stanford University Li Ka Shing Learning and Knowledge Center / Stanford, CA
Cancellation requests must be submitted in writing to Customer Service at firstname.lastname@example.org or mail to AAOS, 9400 W Higgins Rd, Rosemont, IL 60018. Registrants must submit their cancellation two weeks prior to the course start date to receive a full refund.
Please click HERE for additional symposium information.
Symposium Audience: Orthopaedic surgeons and researchers, Young Investigators, and government representatives. Early registration encouraged.
There is substantial interest in using biologics to reduce body and joint pain and to accelerate healing from orthopaedic injuries and surgery. Musculoskeletal problems attributed to injuries and aging are the leading cause of disability in the United States. In recent years, there has been an exponential rise in the use of biologics to treat therapies such as platelet rich plasma (PRP), that are not required to undergo pre-market approval/clearance from the Food and Drug Administration. Consequently, clinical use of these treatments has greatly outpaced evidence from the American Association for the Advancement of Science. The orthopaedic professional societies and research communities share these concerns. To address these concerns, Optimizing Clinical Use of Biologics in Orthopaedic Surgery Research Symposium will be a collaborative and interactive meeting to develop a collective impact agenda to promote informed regulation and funding of new pathways for the clinical evaluation of biologics. Specifically, the symposium aims to determine candidate biologic targets for common orthopaedic conditions and injuries, identify a process to determine what is known about the composition and biologic activity of biologics using PRP as a model, determine the feasibility of establishing a clinical registry to collect data on the use of biologics, and identify regulatory pathways to facilitate their use. Symposium faculty and participants will consider clinical trial designs to include use of adaptive clinical trials to test the efficacy of PRP.